Firm Record
GlaxoSmithKline Biologicals SA
14 findings from 3 inspection documents published by regulators. Each row below says what its date means.
US FDA · 2026-10-20 ~ 2026-10-30
Areas cited
Published inspection documents
21 CFR sections cited in FDA inspections
Citations from 2 FDA inspections (2022-09-13~2024-03-12) of facilities listed under this company name in FDA's inspection citation data.
| As written by FDA | Inspection | Latest inspection | |
|---|---|---|---|
| 21 CFR 211.170(b) | Annual visual exams of drug products | 1 | 2024-03-12 |
| 21 CFR 211.192 | Investigations of discrepancies, failures | 1 | 2024-03-12 |
| 21 CFR 211.67(b)(6) | Cleaning SOP/inspection | 1 | 2024-03-12 |
| 21 CFR 211.67(c) | Cleaning/maintenance records not kept | 1 | 2022-09-13 |
1 site: GlaxoSmithKline Biologicals (Saint-Amand-Les-Eaux, France) · 2 inspections
Source: FDA Data Dashboard - Inspections Citations, as of 2026-11-08. Only inspections with at least one citation are included, and a section cited more than once in one inspection counts once. Only facilities whose name and legal form match this page's documents, and that are listed in a single country, are included.
Other companies with similar findings
Other companies with findings worded closely to this company's. Only documents of the same type are compared.
A record as of publication. Check the agency's own announcements for any later corrective action.
What is included. As collected on 2026-11-15: only documents with a detail page (3 or more findings). See the firm lookup for everything.